Swissmedic has issued a communication regarding a packaging error identified on Voxzogo (vosoritidum) outer packaging. The error involves incorrect milligram (mg) indications for the active ingredient Vosoritid, with 0.4 mg printed instead of the correct 0.56 mg or 1.2 mg. Additionally, the concentration after reconstitution is incorrectly stated as 0.8 mg/ml instead of 2 mg/ml on the 1.2 mg packaging. Several specific batch numbers have been identified as affected by this labeling defect.

Healthcare providers and potentially patients who have received affected batches should be aware of this discrepancy. While the error is in the packaging text and not the product itself, it is crucial to refer to the company's information letter for precise details on the affected batches and any recommended actions. This notice serves to inform professionals about the identified issue and ensure awareness of the correct product specifications.